Dr. Tewari among newly appointed urologists

Several urologists have been appointed to new posts across the country.

Ashutosh K. Tewari, MB, BS, has been named to lead Presbyterian Hospital and Weill Cornell Medical College’s newly established Center for Prostate Cancer at New York-Presbyterian/Weill Cornell Medical Center, which is dedicated to research on prostate cancer and its treatment.

Dr. Tewari is current director of the LeFrak Center for Robotic Surgery at New York-Presbyterian/Weill Cornell Medical Center and professor of urologic oncology and public health at Weill Cornell Medical College.

"There are many research programs that are directed toward advanced prostate cancer," Dr. Tewari said. "My main focus is to not let anyone get to an advanced cancer stage; therefore, we will use a combination of imaging, genomics, surgery and novel therapies to augment our surgical results and thus improve survival while maintaining quality of life."

The center's clinical services include advanced screening and diagnostic methods, such as fusion biopsy, focal therapy for localized tumors, refined imaging techniques, open and robotic surgery, treatments for advanced prostate cancer, and rehabilitation for urinary and sexual issues following treatment.

In Owings Mills, MD, Chesapeake Urology Associates, P.A. has announced that Dr. Keith J. O'Reilly, MD, has joined the practice. Dr. O'Reilly will continue to serve patients from his existing office in Westminster, MD.

Dr. O'Reilly has been practicing urology in Maryland since 2006 and treats all aspects of adult urology. His special interests are minimally invasive surgery, including robotic surgery, the management of stone disease, and urinary incontinence in men and women.

Absorption Pharmaceuticals, Huntington Beach, CA, announced that Laurence A. Levine, MD, will assume the role of chief medical officer.

Absorption is the maker of Promescent, an FDA-approved topical treatment for premature ejaculation.

Dr. Levine is professor of urology at the Rush University Medical Center in Chicago, and is in private practice with Uropartners, LLC. At Absorption, he will oversee the company's growth and education efforts, with a focus on getting Promescent written into protocols as a top-line treatment for premature ejaculation nationwide, the company said.

Promescent is a lidocaine-based spray for premature ejaculation designed to absorb below the surface of the skin where nerve endings that control ejaculation are located, ultimately prolonging the time period of intercourse.